Presented By Christina Tsien at 2014 ASCO Annual Meeting
Current Limitations in the Response Assessment of Anti-Angiogenic Therapy
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Imaging Changes Following Anti-Angiogenic Therapy
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Does Reduction in Enhancement Reflect Anti-Tumor Effect?
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Recurrent GBM treated with Bevacizumab: CE-Δ T1-weighted Subtraction Maps Aid Prediction of Survival in a Multi-Center Clinical Trial
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Improved Response Rates with Anti-Angiogenic Therapies Does Not Correlate to Improved OS
Presented By Christina Tsien at 2014 ASCO Annual Meeting
<br />Physiologic MRI: Imaging Tumor Biology May Improve Response Assessment
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Slide 8
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Bi-modal fitted ADC Histogram Analysis Predict 6 mth PFS in Recurrent GBM Tx with Bevacizumab
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Bevacizumab Decreases Edema Leading to Improved Clinical Benefit
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Vessel Architectural Imaging
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Summary
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Imaging Biomarkers Ready for Prime Time?
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Physiologic Imaging Biomarkers must add value beyond known Clinical Predictors of OS
Presented By Christina Tsien at 2014 ASCO Annual Meeting
What are the Challenges in Incorporating Imaging Biomarkers in the Clinic Today?
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Diffusion MRI
Presented By Christina Tsien at 2014 ASCO Annual Meeting
Summary
Presented By Christina Tsien at 2014 ASCO Annual Meeting